Moberg Pharma’s head of U.S. operations to resign by end of January 2015
Moberg Pharma AB (OMX:MOB) today announced that its head of U.S. operations, Steve Cagle, has announced his resignation. In order to secure a smooth transition, he will remain in his position until end of January 2015 at the latest."I am proud of the achievements during the last two years. We have almost doubled the net sales in the U.S. market and made Kerasal Nail® the leading OTC product for nail fungus related problems", said Steve Cagle."Steve and his team have made an excellent job in growing our U.S. business. Our U.S. sales outpaced the market and grew with 31% in the past 12